{"hands_on_practices": [{"introduction": "Understanding the true scale of a rare disease is the foundational first step in translational research, guiding resource allocation and drug development strategy. Simple prevalence estimates often fail to capture the complex reality of human populations. This exercise [@problem_id:5072569] demonstrates how to build a more accurate estimate of disease burden by integrating core principles of population genetics, such as demographic stratification, varying allele frequencies, and the effects of inbreeding.", "problem": "Consider a monogenic rare disease, RD-X, that follows autosomal recessive (AR) inheritance with incomplete penetrance. Assume the population is partitioned into three demographic strata indexed by $i \\in \\{1,2,3\\}$, each characterized by an AR risk allele frequency $q_i$, an inbreeding coefficient $F_i$, and a population weight $w_i$ such that $\\sum_{i=1}^{3} w_i = 1$. Under the Hardyâ€“Weinberg Equilibrium (HWE) with inbreeding, the probability of being AR homozygous ($aa$) in stratum $i$ is $q_i^{2} + F_i q_i (1 - q_i)$. Let clinical penetrance be $\\pi \\in (0,1)$, so the probability that an individual in stratum $i$ is clinically affected is $\\pi \\left(q_i^{2} + F_i q_i (1 - q_i)\\right)$. The total population size is $N$, and the stratum sizes are $N_i = w_i N$.\n\nYou are given the following scientifically plausible parameters for a country with genetic diversity and varying consanguinity practices:\n- Total population size $N = 68{,}000{,}000$.\n- Penetrance $\\pi = 0.8$.\n- Stratum $1$: $w_1 = 0.60$, $q_1 = 0.004$, $F_1 = 0$.\n- Stratum $2$: $w_2 = 0.35$, $q_2 = 0.002$, $F_2 = 0.01$.\n- Stratum $3$: $w_3 = 0.05$, $q_3 = 0.03$, $F_3 = 0.02$.\n\nStarting from first principles of the linearity of expectation and the probabilistic definition of prevalence as disease risk, derive the expected number of individuals with RD-X in the country by aggregating across strata. Provide the final expected number in the unit \"individuals\" and round your answer to four significant figures. In addition, briefly justify how demographic heterogeneity (differences in $w_i$, $q_i$, and $F_i$) affects the aggregated estimate without assuming any shortcuts beyond the stated foundations.", "solution": "The problem is assessed to be scientifically grounded, well-posed, and objective. All necessary data are provided, and the premises are consistent with established principles of population genetics. The problem is valid.\n\nThe objective is to derive the expected total number of individuals with the rare disease RD-X in a demographically stratified population. We begin from the first principles as requested.\n\nLet $X$ be the random variable representing the total number of clinically affected individuals in the country. The country's population is partitioned into $3$ disjoint strata, so we can define $X_i$ as the number of affected individuals in stratum $i$, for $i \\in \\{1, 2, 3\\}$. The total number of affected individuals is the sum of those in each stratum:\n$$X = X_1 + X_2 + X_3 = \\sum_{i=1}^{3} X_i$$\nBy the linearity of expectation, the expected total number of affected individuals is the sum of the expectations for each stratum:\n$$E[X] = E\\left[\\sum_{i=1}^{3} X_i\\right] = \\sum_{i=1}^{3} E[X_i]$$\nNow, we must find the expected number of affected individuals, $E[X_i]$, within each stratum $i$. The population of stratum $i$ is $N_i = w_i N$, where $N$ is the total population size and $w_i$ is the population weight of the stratum. For any individual chosen randomly from stratum $i$, the probability of being clinically affected is defined as the disease prevalence in that stratum, let's call it $P_{\\text{aff},i}$. According to the problem statement, this probability is given by:\n$$P_{\\text{aff},i} = \\pi \\left(q_i^{2} + F_i q_i (1 - q_i)\\right)$$\nwhere $\\pi$ is the clinical penetrance, $q_i$ is the risk allele frequency, and $F_i$ is the inbreeding coefficient for stratum $i$.\n\nThe number of affected individuals in stratum $i$, $X_i$, can be modeled as a sum of indicator random variables. Let $A_{ij} = 1$ if the $j$-th individual in stratum $i$ is affected, and $A_{ij} = 0$ otherwise, for $j \\in \\{1, \\dots, N_i\\}$. Then $X_i = \\sum_{j=1}^{N_i} A_{ij}$. The expectation of each indicator variable is $E[A_{ij}] = P(A_{ij}=1) = P_{\\text{aff},i}$. Using the linearity of expectation for $X_i$:\n$$E[X_i] = E\\left[\\sum_{j=1}^{N_i} A_{ij}\\right] = \\sum_{j=1}^{N_i} E[A_{ij}] = N_i \\cdot P_{\\text{aff},i}$$\nSubstituting $N_i = w_i N$ and the expression for $P_{\\text{aff},i}$:\n$$E[X_i] = (w_i N) \\cdot \\pi \\left(q_i^{2} + F_i q_i (1 - q_i)\\right)$$\nFinally, the total expected number of affected individuals in the country is the sum over all strata:\n$$E[X] = \\sum_{i=1}^{3} E[X_i] = \\sum_{i=1}^{3} w_i N \\pi \\left(q_i^{2} + F_i q_i (1 - q_i)\\right)$$\nFactoring out the constants $N$ and $\\pi$, we get the final expression for our calculation:\n$$E[X] = N \\pi \\sum_{i=1}^{3} w_i \\left(q_i^{2} + F_i q_i (1 - q_i)\\right)$$\nNow we substitute the given numerical values:\n- $N = 68,000,000$\n- $\\pi = 0.8$\n- Stratum $1$: $w_1 = 0.60$, $q_1 = 0.004$, $F_1 = 0$\n- Stratum $2$: $w_2 = 0.35$, $q_2 = 0.002$, $F_2 = 0.01$\n- Stratum $3$: $w_3 = 0.05$, $q_3 = 0.03$, $F_3 = 0.02$\n\nWe calculate the term inside the summation for each stratum:\nFor stratum $1$:\n$$w_1 \\left(q_1^{2} + F_1 q_1 (1 - q_1)\\right) = 0.60 \\left( (0.004)^{2} + 0 \\cdot (0.004)(1-0.004) \\right) = 0.60 \\cdot (0.000016) = 0.0000096$$\nFor stratum $2$:\n$$w_2 \\left(q_2^{2} + F_2 q_2 (1 - q_2)\\right) = 0.35 \\left( (0.002)^{2} + (0.01)(0.002)(1-0.002) \\right)$$\n$$= 0.35 \\left( 0.000004 + 0.00002 \\cdot 0.998 \\right) = 0.35 \\left( 0.000004 + 0.00001996 \\right) = 0.35 \\cdot (0.00002396) \\approx 0.000008386$$\nFor stratum $3$:\n$$w_3 \\left(q_3^{2} + F_3 q_3 (1 - q_3)\\right) = 0.05 \\left( (0.03)^{2} + (0.02)(0.03)(1-0.03) \\right)$$\n$$= 0.05 \\left( 0.0009 + 0.0006 \\cdot 0.97 \\right) = 0.05 \\left( 0.0009 + 0.000582 \\right) = 0.05 \\cdot (0.001482) = 0.0000741$$\nThe sum of these terms is:\n$$\\sum_{i=1}^{3} (\\dots) = 0.0000096 + 0.000008386 + 0.0000741 = 0.000092086$$\nThis sum represents the overall population prevalence of the AR homozygous genotype, averaged across strata. Now, we calculate the total expected number of affected individuals:\n$$E[X] = N \\pi \\cdot (0.000092086) = 68,000,000 \\cdot 0.8 \\cdot 0.000092086$$\n$$E[X] = 54,400,000 \\cdot 0.000092086 = 5009.4784$$\nRounding the final answer to four significant figures gives $5009$.\n\nRegarding the effect of demographic heterogeneity: The aggregated estimate is derived by summing the expected number of cases from each stratum. This approach is necessary because the prevalence of the disease is a non-linear function of the underlying genetic parameters, specifically the allele frequency $q_i$ and the inbreeding coefficient $F_i$. The total expected number of cases is proportional to the weighted average of stratum-specific prevalences, $\\sum w_i P_{\\text{aff},i}$. A naive approach might be to first average the parameters across strata (e.g., $\\bar{q} = \\sum w_i q_i$, $\\bar{F} = \\sum w_i F_i$) and then compute a single prevalence estimate for the entire population. This would be incorrect and yield a different result because, in general, $\\sum w_i f(q_i, F_i) \\neq f(\\sum w_i q_i, \\sum w_i F_i)$ for a non-linear function $f$.\nThe dominant non-linear term is $q_i^2$. Due to the convexity of the function $x \\mapsto x^2$, Jensen's inequality implies that the weighted average of the squares is greater than or equal to the square of the weighted average: $\\sum w_i q_i^2 \\ge (\\sum w_i q_i)^2$. This means that ignoring the stratification and using an average allele frequency will typically underestimate the number of homozygotes (this is known as the Wahlund effect). In this problem, stratum $3$ has a much higher allele frequency ($q_3=0.03$) and inbreeding coefficient ($F_3=0.02$) than the other strata. Although it represents only $5\\%$ of the population, its contribution to the overall genotype prevalence ($0.0000741$) is substantially larger than that of the other two strata combined ($0.0000096 + 0.000008386 = 0.000017986$). Heterogeneity thus allows small, high-risk subpopulations to contribute disproportionately to the total disease burden, an effect that is only captured by the correct stratum-by-stratum aggregation.", "answer": "$$\\boxed{5009}$$", "id": "5072569"}, {"introduction": "Once the potential burden of a rare disease is estimated, a critical translational challenge is to identify affected individuals, often through population-wide screening. However, the statistical reliability of a screening test is profoundly influenced by the disease's prevalence. This practice [@problem_id:5072571] uses Bayes' theorem to calculate a test's Positive Predictive Value ($PPV$), revealing the counterintuitive reality that in low-prevalence settings, even highly accurate tests can yield a large proportion of false positives.", "problem": "A national translational program is evaluating a high-throughput genomic screening assay for a monogenic rare disease, denoted as event $D$ for \"individual has the disease.\" The assay outputs a binary result: event $T^{+}$ for \"test is positive.\" The assay has sensitivity $S_{e}$ and specificity $S_{p}$, defined by the core diagnostic test properties: $S_{e} = \\mathbb{P}(T^{+} \\mid D)$ and $S_{p} = \\mathbb{P}(T^{-} \\mid \\neg D)$, where $\\neg D$ denotes \"individual does not have the disease.\" The disease prevalence in the target newborn population is $p = \\mathbb{P}(D)$. The translational medicine team is concerned about rare disease contexts where $p$ is very small, and aims to quantify how this affects the Positive Predictive Value (PPV), defined as $\\mathbb{P}(D \\mid T^{+})$, in order to assess downstream confirmatory testing burden and ethical implications of false positives.\n\nStarting from Bayes' theorem and the stated core definitions of sensitivity, specificity, and prevalence, derive a formula for $\\mathbb{P}(D \\mid T^{+})$ in terms of $S_{e}$, $S_{p}$, and $p$, and then compute $\\mathbb{P}(D \\mid T^{+})$ for the following scientifically plausible parameters of the screening assay in a general newborn population: $S_{e} = 0.95$, $S_{p} = 0.995$, and $p = 5 \\times 10^{-5}$ (one in $20{,}000$). Report your final numeric value for $\\mathbb{P}(D \\mid T^{+})$ as a decimal rounded to four significant figures. Do not use a percentage sign.", "solution": "We begin from Bayes' theorem for events $D$ and $T^{+}$:\n$$\n\\mathbb{P}(D \\mid T^{+}) = \\frac{\\mathbb{P}(T^{+} \\mid D)\\,\\mathbb{P}(D)}{\\mathbb{P}(T^{+})}.\n$$\nThe denominator can be expanded using the law of total probability over the partition $\\{D, \\neg D\\}$:\n$$\n\\mathbb{P}(T^{+}) = \\mathbb{P}(T^{+} \\mid D)\\,\\mathbb{P}(D) + \\mathbb{P}(T^{+} \\mid \\neg D)\\,\\mathbb{P}(\\neg D).\n$$\nBy definition, sensitivity $S_{e} = \\mathbb{P}(T^{+} \\mid D)$ and specificity $S_{p} = \\mathbb{P}(T^{-} \\mid \\neg D)$. Therefore, $\\mathbb{P}(T^{+} \\mid \\neg D) = 1 - S_{p}$. Also, prevalence $p = \\mathbb{P}(D)$ implies $\\mathbb{P}(\\neg D) = 1 - p$.\n\nSubstituting these into Bayes' theorem yields:\n$$\n\\mathbb{P}(D \\mid T^{+}) = \\frac{S_{e}\\,p}{S_{e}\\,p + (1 - S_{p})\\,(1 - p)}.\n$$\nThis expression is the Positive Predictive Value (PPV) in terms of sensitivity, specificity, and prevalence, derived from fundamental probability laws.\n\nNow we substitute the given numerical values, keeping symbolic structure until the final step:\n- $S_{e} = 0.95$,\n- $S_{p} = 0.995$,\n- $p = 5 \\times 10^{-5}$.\n\nCompute the numerator:\n$$\n\\text{num} = S_{e}\\,p = 0.95 \\times \\left(5 \\times 10^{-5}\\right) = 0.0000475.\n$$\nCompute the false positive component in the denominator:\n$$\n1 - S_{p} = 1 - 0.995 = 0.005,\\quad 1 - p = 1 - 5 \\times 10^{-5} = 0.99995,\n$$\nso\n$$\n\\text{fp} = (1 - S_{p})\\,(1 - p) = 0.005 \\times 0.99995 = 0.00499975.\n$$\nCompute the denominator:\n$$\n\\text{den} = \\text{num} + \\text{fp} = 0.0000475 + 0.00499975 = 0.00504725.\n$$\nTherefore,\n$$\n\\mathbb{P}(D \\mid T^{+}) = \\frac{0.0000475}{0.00504725}.\n$$\nPerforming the division gives\n$$\n\\mathbb{P}(D \\mid T^{+}) \\approx 0.009411065\\ldots\n$$\nRounded to four significant figures and expressed as a decimal (without a percentage sign), this is\n$$\n0.009411.\n$$\n\nInterpretation in low-prevalence settings: Even with high sensitivity and high specificity, when prevalence $p$ is very small, the term $(1 - S_{p})(1 - p)$ in the denominator can dominate the true positive term $S_{e}p$, making $\\mathbb{P}(D \\mid T^{+})$ small. Here, despite $S_{e} = 0.95$ and $S_{p} = 0.995$, the PPV is approximately $0.009411$, meaning the majority of positive screens are false positives, underscoring a core translational challenge for rare disease screening: substantial confirmatory testing burden, potential anxiety, and ethical considerations arising from low PPV at population scale.", "answer": "$$\\boxed{0.009411}$$", "id": "5072571"}, {"introduction": "Moving from identification to intervention, the development of novel treatments like gene therapy requires rigorous quantitative modeling to ensure safety and efficacy. This hands-on practice [@problem_id:5072512] guides you through the process of creating a dose-response model for an AAV-based gene therapy. By combining a Poisson model for cellular transduction with preclinical scaling factors, you will determine the minimal therapeutic dose required to achieve a clinical benefit, a crucial calculation for designing first-in-human trials.", "problem": "A rare monogenic hepatometabolic disease requires restoring a minimum fraction of normal hepatic enzyme activity to achieve clinical benefit. Consider an Adeno-Associated Virus (AAV) gene addition therapy that delivers vector genomes per kilogram to the patient at dose $D$ (in vector genomes per kilogram, written as vg/kg). Assume the following foundational principles and facts:\n\n- The Central Dogma of molecular biology states that gene delivery enabling transcription and translation in hepatocytes yields enzyme production, and phenotypic correction occurs once the mean tissue enzyme activity reaches a threshold fraction of normal.\n- For hepatocyte transduction by AAV vectors, the number of delivered vector genomes per hepatocyte, $K$, is well modeled by a Poisson random variable with mean $\\lambda$. The mean multiplicity of delivery scales linearly with dose, so $\\lambda = \\alpha_{\\text{human}} D$, where $\\alpha_{\\text{human}}$ is a per-dose transduction parameter in humans.\n- A hepatocyte that receives at least one functional vector genome expresses the therapeutic enzyme near a promoter-specified plateau equal to $\\gamma E_{\\text{norm}}$, where $E_{\\text{norm}}$ is the normal (healthy) mean enzyme activity per hepatocyte, $0 < \\gamma \\leq 1$. Additional vector genomes do not increase enzyme expression beyond this plateau. Non-transduced hepatocytes produce $0$ therapeutic enzyme.\n- Translational efficiency from non-human primates to humans is reduced by a scaling factor $s \\in (0,1)$, so $\\alpha_{\\text{human}} = s \\alpha_{\\text{NHP}}$, where $\\alpha_{\\text{NHP}}$ is the non-human primate calibration constant.\n\nYou are given the following scientifically plausible parameter values derived from preclinical calibration and promoter characterization:\n- $\\alpha_{\\text{NHP}} = 3.5 \\times 10^{-14}$,\n- $s = 0.63$,\n- $\\gamma = 0.65$,\n- The therapeutic threshold for clinical benefit is $\\theta = 0.35$, meaning the mean hepatic activity must be at least $\\theta E_{\\text{norm}}$.\n\nUsing these assumptions and parameter values, derive from first principles an expression for the mean hepatic enzyme activity as a function of $D$, and determine the minimal dose $D$ (in vg/kg) such that the mean activity meets the threshold $\\theta E_{\\text{norm}}$. Round your final numerical result to three significant figures. Express the dose in vector genomes per kilogram (vg/kg).", "solution": "The problem asks for an expression for the mean hepatic enzyme activity as a function of dose $D$, and for the minimal dose $D$ required to achieve a therapeutic threshold. The first step is to validate the problem statement.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- Dose of gene therapy: $D$, in vector genomes per kilogram (vg/kg).\n- Number of delivered vector genomes per hepatocyte: $K$.\n- $K$ is a Poisson random variable with mean $\\lambda$.\n- Mean multiplicity of delivery: $\\lambda = \\alpha_{\\text{human}} D$.\n- Enzyme expression in a hepatocyte with $K \\geq 1$ genomes: $\\gamma E_{\\text{norm}}$.\n- Enzyme expression in a hepatocyte with $K = 0$ genomes: $0$.\n- $E_{\\text{norm}}$ is the normal mean enzyme activity per hepatocyte.\n- $0 < \\gamma \\leq 1$ is a promoter-specified plateau factor.\n- Translational efficiency scaling: $\\alpha_{\\text{human}} = s \\alpha_{\\text{NHP}}$, where $s \\in (0,1)$.\n- Therapeutic threshold for mean hepatic activity: $\\theta E_{\\text{norm}}$.\n- Parameter values:\n  - $\\alpha_{\\text{NHP}} = 3.5 \\times 10^{-14}$\n  - $s = 0.63$\n  - $\\gamma = 0.65$\n  - $\\theta = 0.35$\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, drawing principles from molecular biology (Central Dogma), virology (AAV transduction), and probability theory (Poisson distribution). The use of a Poisson model for random, independent events like viral particle delivery to cells is a standard and well-accepted assumption in the field of gene therapy modeling. The concept of scaling efficacy from non-human primate (NHP) models to humans is a critical and realistic aspect of translational medicine. The problem is well-posed, providing all necessary parameters and a clear objective. The language is precise and objective. There are no contradictions, no reliance on pseudoscience, and the parameters provided are stated to be scientifically plausible. The problem is formalizable and requires substantive reasoning.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be derived.\n\n### Derivation of the Solution\n\nLet $K$ be the random variable representing the number of vector genomes delivered to a single hepatocyte. The problem states that $K$ follows a Poisson distribution with mean $\\lambda$. The probability mass function is given by:\n$$\nP(K=k) = \\frac{\\lambda^k e^{-\\lambda}}{k!} \\quad \\text{for } k=0, 1, 2, \\dots\n$$\nThe enzyme activity in a single hepatocyte, which we can denote as $E$, is a function of $K$. Based on the problem description:\n- If $K=0$ (the cell is not transduced), the activity is $E=0$.\n- If $K \\geq 1$ (the cell is transduced), the activity is $E = \\gamma E_{\\text{norm}}$.\n\nThe mean hepatic enzyme activity, $\\langle E \\rangle$, is the expected value of $E$ over the population of hepatocytes. We can calculate this using the law of total expectation:\n$$\n\\langle E \\rangle = E[E] = (0) \\cdot P(K=0) + (\\gamma E_{\\text{norm}}) \\cdot P(K \\geq 1)\n$$\nThe probability that a hepatocyte receives zero vector genomes ($K=0$) is found from the Poisson distribution:\n$$\nP(K=0) = \\frac{\\lambda^0 e^{-\\lambda}}{0!} = e^{-\\lambda}\n$$\nThe probability that a hepatocyte receives at least one vector genome is the complement of receiving zero genomes:\n$$\nP(K \\geq 1) = 1 - P(K=0) = 1 - e^{-\\lambda}\n$$\nThis term, $1 - e^{-\\lambda}$, represents the fraction of hepatocytes that are successfully transduced.\n\nSubstituting this into the expression for the mean activity $\\langle E \\rangle$:\n$$\n\\langle E \\rangle = (\\gamma E_{\\text{norm}}) (1 - e^{-\\lambda})\n$$\nThe problem states that the mean multiplicity $\\lambda$ is a function of the dose $D$. Specifically, $\\lambda = \\alpha_{\\text{human}} D$, and the human-specific parameter $\\alpha_{\\text{human}}$ is related to the NHP parameter $\\alpha_{\\text{NHP}}$ by the scaling factor $s$: $\\alpha_{\\text{human}} = s \\alpha_{\\text{NHP}}$. Therefore, we can express $\\lambda$ in terms of $D$ and the given preclinical parameters:\n$$\n\\lambda = s \\alpha_{\\text{NHP}} D\n$$\nSubstituting this into our equation for mean activity gives the desired expression for the mean hepatic enzyme activity as a function of dose $D$:\n$$\n\\langle E \\rangle(D) = \\gamma E_{\\text{norm}} \\left(1 - \\exp(-s \\alpha_{\\text{NHP}} D)\\right)\n$$\nThis is the first part of the required derivation.\n\nNext, we must find the minimal dose $D$ such that the mean activity meets or exceeds the therapeutic threshold $\\theta E_{\\text{norm}}$. We set the mean activity equal to the threshold value:\n$$\n\\langle E \\rangle(D) = \\theta E_{\\text{norm}}\n$$\n$$\n\\gamma E_{\\text{norm}} \\left(1 - \\exp(-s \\alpha_{\\text{NHP}} D)\\right) = \\theta E_{\\text{norm}}\n$$\nThe term $E_{\\text{norm}}$ is present on both sides and can be cancelled, as it is non-zero:\n$$\n\\gamma \\left(1 - \\exp(-s \\alpha_{\\text{NHP}} D)\\right) = \\theta\n$$\nWe now solve this equation for $D$:\n$$\n1 - \\exp(-s \\alpha_{\\text{NHP}} D) = \\frac{\\theta}{\\gamma}\n$$\n$$\n\\exp(-s \\alpha_{\\text{NHP}} D) = 1 - \\frac{\\theta}{\\gamma}\n$$\nTaking the natural logarithm of both sides:\n$$\n-s \\alpha_{\\text{NHP}} D = \\ln\\left(1 - \\frac{\\theta}{\\gamma}\\right)\n$$\nFinally, isolating $D$:\n$$\nD = -\\frac{1}{s \\alpha_{\\text{NHP}}} \\ln\\left(1 - \\frac{\\theta}{\\gamma}\\right)\n$$\nThis is the symbolic expression for the minimal required dose.\n\nNow, we substitute the given numerical values:\n- $\\alpha_{\\text{NHP}} = 3.5 \\times 10^{-14}$\n- $s = 0.63$\n- $\\gamma = 0.65$\n- $\\theta = 0.35$\n\nFirst, compute the product in the denominator:\n$$\ns \\alpha_{\\text{NHP}} = (0.63) \\cdot (3.5 \\times 10^{-14}) = 2.205 \\times 10^{-14}\n$$\nNext, compute the term inside the logarithm:\n$$\n1 - \\frac{\\theta}{\\gamma} = 1 - \\frac{0.35}{0.65} = 1 - \\frac{35}{65} = 1 - \\frac{7}{13} = \\frac{6}{13}\n$$\nNow, substitute these values into the expression for $D$:\n$$\nD = -\\frac{1}{2.205 \\times 10^{-14}} \\ln\\left(\\frac{6}{13}\\right)\n$$\nCalculating the value of the logarithm:\n$$\n\\ln\\left(\\frac{6}{13}\\right) \\approx -0.77318041\n$$\nSubstituting this numerical value:\n$$\nD \\approx -\\frac{1}{2.205 \\times 10^{-14}} (-0.77318041)\n$$\n$$\nD \\approx \\frac{0.77318041}{2.205 \\times 10^{-14}} \\approx 3.506487 \\times 10^{13}\n$$\nThe problem requires the final result to be rounded to three significant figures.\n$$\nD \\approx 3.51 \\times 10^{13}\n$$\nThe unit for the dose $D$ is vector genomes per kilogram (vg/kg).", "answer": "$$\\boxed{3.51 \\times 10^{13}}$$", "id": "5072512"}]}